Therapeutic Strategies Based on Glucagon-Like Peptide 1

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

2002 • 1,295 citations

Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes

1986 • 1,275 citations

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.

1999 • 1,207 citations

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1993 • 1,119 citations

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

1995 • 1,064 citations

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

1993 • 1,064 citations

Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV

2003 • 913 citations

Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients

2001 • 881 citations

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.

1987 • 814 citations

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans

1997 • 799 citations

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

1995 • 741 citations

Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes

2004 • 718 citations

Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects

1995 • 705 citations

Glucagon-Like Peptide 1 Inhibits Cell Apoptosis and Improves Glucose Responsiveness of Freshly Isolated Human Islets

2003 • 660 citations

Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration

2000 • 644 citations

Hamster preproglucagon contains the sequence of glucagon and two related peptides

1983 • 602 citations

A Meta-Analysis of the Effect of Glucagon-Like Peptide-1 (7–36) Amide on Ad Libitum Energy Intake in Humans

2001 • 590 citations

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.

2000 • 590 citations

Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis

2002 • 583 citations

Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut

1987 • 566 citations

Glucagon-Like Peptide-1-(7–36)Amide Is Transformed to Glucagon-Like Peptide-1-(9–36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine¹

1999 • 566 citations

Glucagon-like peptide-1: a potent regulator of food intake in humans

1999 • 564 citations

Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes

2003 • 556 citations

Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers

2002 • 553 citations

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26

2000 • 540 citations

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.

1998 • 480 citations

Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pig Small Intestine but Not Pancreas*

1986 • 475 citations

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

2001 • 469 citations

Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects

2003 • 431 citations

Glucagon-Like Peptide-1 Induces Cell Proliferation and Pancreatic-Duodenum Homeobox-1 Expression and Increases Endocrine Cell Mass in the Pancreas of Old, Glucose-Intolerant Rats

2000 • 427 citations

One Week’s Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and α- and β-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes

2004 • 427 citations

Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control Over a 4-Week Study Period in Type 2 Diabetes

2002 • 425 citations

Glucagon-Like Peptide-1 and Exendin-4 Stimulate β-Cell Neogenesis in Streptozotocin-Treated Newborn Rats Resulting in Persistently Improved Glucose Homeostasis at Adult Age

2001 • 367 citations

Effect on Glycemic Control of Exenatide (Synthetic Exendin-4) Additive to Existing Metformin and/or Sulfonylurea Treatment in Patients With Type 2 Diabetes

2003 • 358 citations

Dipeptidyl Peptidase IV Inhibitor Treatment Stimulates β-Cell Survival and Islet Neogenesis in Streptozotocin-Induced Diabetic Rats

2003 • 337 citations

Alternative routes of insulin delivery

2003 • 331 citations

CD26: a surface protease involved in T-cell activation

1994 • 330 citations

Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells.

1999 • 326 citations

Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells.

1992 • 323 citations

Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice

2002 • 318 citations

Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211)

2004 • 318 citations

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

1998 • 309 citations

Double Incretin Receptor Knockout (DIRKO) Mice Reveal an Essential Role for the Enteroinsular Axis in Transducing the Glucoregulatory Actions of DPP-IV Inhibitors

2004 • 300 citations

Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats

2000 • 295 citations

Persistent Improvement of Type 2 Diabetes in the Goto-Kakizaki Rat Model by Expansion of the β-Cell Mass During the Prediabetic Period With Glucagon-Like Peptide-1 or Exendin-4

2002 • 288 citations

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM

1996 • 286 citations

Glucagon-Like Peptide I Receptors in the Subfornical Organ and the Area Postrema Are Accessible to Circulating Glucagon-Like Peptide I

1996 • 286 citations

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice

2002 • 280 citations

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

1998 • 279 citations

Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes

2002 • 269 citations

Neonatal Exendin-4 Prevents the Development of Diabetes in the Intrauterine Growth Retarded Rat

2003 • 265 citations

Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide

1998 • 260 citations

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

1996 • 248 citations

Long-Term Treatment With the Dipeptidyl Peptidase IV Inhibitor P32/98 Causes Sustained Improvements in Glucose Tolerance, Insulin Sensitivity, Hyperinsulinemia, and β-Cell Glucose Responsiveness in VDF (fa/fa) Zucker Rats

2002 • 237 citations

Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides

1995 • 221 citations

The GLP-1 Derivative NN2211 Restores β-Cell Sensitivity to Glucose in Type 2 Diabetic Patients After a Single Dose

2003 • 216 citations

Development and Characterization of a Glucagon-Like Peptide 1-Albumin Conjugate

2003 • 213 citations

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

1999 • 212 citations

Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice

2002 • 204 citations

Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells

2004 • 203 citations

Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice

2000 • 196 citations

GLP‐1 derivative liraglutide in rats with β‐cell deficiencies: influence of metabolic state on β‐cell mass dynamics

2003 • 195 citations

Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons

2003 • 193 citations

Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations

1999 • 192 citations

Chronic Inhibition of Circulating Dipeptidyl Peptidase IV by FE 999011 Delays the Occurrence of Diabetes in Male Zucker Diabetic Fatty Rats

2002 • 170 citations

Effects of GLP-1-(7–36)NH₂, GLP-1-(7–37), and GLP-1- (9–36)NH₂on Intravenous Glucose Tolerance and Glucose-Induced Insulin Secretion in Healthy Humans

2003 • 162 citations

Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1

2002 • 161 citations

Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs

2002 • 149 citations

Dipeptidyl Peptidase IV Inhibition Reduces the Degradation and Clearance of GIP and Potentiates Its Insulinotropic and Antihyperglycemic Effects in Anesthetized Pigs

2001 • 145 citations

Long-Term Treatment With Dipeptidyl Peptidase IV Inhibitor Improves Hepatic and Peripheral Insulin Sensitivity in the VDF Zucker Rat

2002 • 144 citations

RyR2 and Calpain-10 Delineate a Novel Apoptosis Pathway in Pancreatic Islets

2004 • 143 citations

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

1998 • 115 citations

Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1

1999 • 105 citations

GLP-1-(9–36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion

2002 • 103 citations

Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes

2003 • 84 citations

GLP-1 Tablet in Type 2 Diabetes in Fasting and Postprandial Conditions

1997 • 80 citations

Endoproteolysis of Glucagon-like Peptide (GLP)-1(7–36) amide by Ectopeptidases in RINm5F Cells

1997 • 69 citations

Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I

1996 • 47 citations

Neutral Endopeptidase 24.11 and Dipeptidyl Peptidase IV are Both Involved in Regulating the Metabolic Stability of Glucagon-like Peptide-1 in vivo

2005 • 18 citations

Cited By (0)

No citing papers found in database